MedTrace Logo

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-05-15

No results posted yet for this study

Summary

The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.

Conditions

Interventions

DRUG

Risperdal Consta (drug)

BEHAVIORAL

Social Skills Training

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Steven M Silverstein, Ph.D. · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148083 on ClinicalTrials.gov